Human serum albumin mutant
AssigneeJCR Pharmaceuticals Co., Ltd.
InventorsKenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
Life of this patent
Estimating the term…
Loading patent…
AssigneeJCR Pharmaceuticals Co., Ltd.
InventorsKenichi Takahashi, Aya Yoshioka, Hideto Morimoto, Masafumi Kinoshita
Estimating the term…
Disclosed are a human serum albumin mutant that can be linked to a physiologically active protein to increase the stability of the protein in the blood, as well as a resulting protein produced by linking with the mutant. The protein produced by linking with the mutant consists of a human serum albumin mutant comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence that, in comparison with it, lacks not more than 10 amino acid residues and/or has not more than 10 amino acid residues replaced, with the proviso that the asparagine residue occurring at position 318 and the threonine at position 320 from the N-terminus of the amino acid sequence set forth as SEQ ID NO:3 are preserved and linked by peptide bonds via a single amino acid residue (X) except proline placed between those two amino acid residues, and a physiologically active protein linked to the mutant.
A human serum albumin mutant-linked protein (A), the human serum albumin mutant linked protein (A) comprising a first polypeptide chain and a second polypeptide chain,
Dependencies are inferred from the claim text.